Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay ( CiPA ) paradigm with an established anti‐seizure medication: Levetiracetam case study
Pharmacology Research & Perspectives · 2023
DOI: 10.1002/prp2.1059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2023. Verfasst von Annie Delaunois und 11 weiteren Autor:innen. Beteiligte Einrichtung: Development Sciences, UCB Biopharma SRL, Braine-l'Alleud, Belgium. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Long QT Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, National Centre for the Replacement Refinement and Reduction of Animals in Research.
Abstract (Originalsprache)
Levetiracetam (LEV), a well‐established anti‐seizure medication (ASM), was launched before the original ICH S7B nonclinical guidance assessing QT prolongation potential and the introduction of the Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm. No information was available on its effects on cardiac channels. The goal of this work was to “pressure test” the CiPA approach with LEV and check the concordance of nonclinical core and follow‐up S7B assays with clinical and post‐marketing data. The following experiments were conducted with LEV (0.25–7.5 mM): patch clamp assays on hERG (acute or trafficking effects), Na V 1.5, Ca V 1.2, K ir 2.1, K V 7.1/mink, K V 1.5, K V 4.3, and HCN4; in silico electrophysiology modeling (Virtual Assay® software) in control, large‐variability, and high‐risk human ventricular cell populations; electrophysiology measurements in human induced pluripotent stem cell (hiPSC)‐derived cardiomyocytes and dog Purkinje fibers; ECG measurements in conscious telemetered dogs after single oral administration (150, 300, and 600 mg/kg). Except a slight inhibition (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Development Sciences, UCB Biopharma SRL, Braine-l'Alleud, Belgium.
- Patient Safety, UCB Biopharma SRL, Braine-l'Alleud, Belgium.
- Patient Safety, UCB Biosciences GmbH, Monheim, Germany.
- B'SYS GmbH, Witterswil, Switzerland.
- Department of Computer Science, University of Oxford, Oxford, UK.
ORCID-Profile: Annie Delaunois
Förderung
- Wellcome Trust
- National Centre for the Replacement Refinement and Reduction of Animals in Research
Zitieren
APA
Delaunois, A., Mathy, F. X., Cornet, M., Gryshkova, V., Korlowski, C., Bonfitto, F., Koch, J., Schlit, A. F., Hebeisen, S., Passini, E., Rodriguez, B., & Valentin, J. P. (2023). Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay ( CiPA ) paradigm with an established anti‐seizure medication: Levetiracetam case study. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1059
Vancouver
Delaunois A, Mathy FX, Cornet M, Gryshkova V, Korlowski C, Bonfitto F, et al. Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay ( CiPA ) paradigm with an established anti‐seizure medication: Levetiracetam case study. Pharmacology Research & Perspectives. 2023. doi:10.1002/prp2.1059
BibTeX
@article{Delaunois2023,
author = {Delaunois, Annie and Mathy, François-Xavier and Cornet, Miranda and Gryshkova, Vitalina and Korlowski, Chloé and Bonfitto, François and Koch, Juliane and Schlit, Anne-Françoise and Hebeisen, Simon and Passini, Elisa and Rodriguez, Blanca and Valentin, Jean-Pierre},
title = {Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay ( CiPA ) paradigm with an established anti‐seizure medication: Levetiracetam case study},
journal = {Pharmacology Research & Perspectives},
year = {2023},
doi = {10.1002/prp2.1059}
}
EUVIMED